Patents by Inventor Reena Varkey
Reena Varkey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240294666Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: ApplicationFiled: January 17, 2024Publication date: September 5, 2024Inventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M Hurt, David Tice
-
Patent number: 11912782Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: March 29, 2021Date of Patent: February 27, 2024Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Patent number: 11529415Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: February 5, 2020Date of Patent: December 20, 2022Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 11203633Abstract: This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind to Pseudomonas PcrV as well as vectors and host cells comprising the same.Type: GrantFiled: February 13, 2020Date of Patent: December 21, 2021Assignee: MedImmune LimitedInventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha S. Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
-
Patent number: 10988546Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: July 31, 2018Date of Patent: April 27, 2021Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Patent number: 10775388Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.Type: GrantFiled: February 5, 2015Date of Patent: September 15, 2020Assignees: MEDIMMUNE, LLC, ABBOTT LABORATORIESInventors: Partha S. Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker, Gerard Davis, Nicolette Jeanblanc, Susan Brophy, Bruce Dille
-
Publication number: 20200164069Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: February 5, 2020Publication date: May 28, 2020Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10597439Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: GrantFiled: November 6, 2012Date of Patent: March 24, 2020Assignee: MEDIMMUNE LIMITEDInventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainey, Cuihua Gao
-
Patent number: 10588969Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: June 11, 2018Date of Patent: March 17, 2020Assignee: Boston Pharmaceuticals, Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20180318416Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: June 11, 2018Publication date: November 8, 2018Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10022443Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: April 7, 2015Date of Patent: July 17, 2018Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20180196065Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.Type: ApplicationFiled: February 5, 2015Publication date: July 12, 2018Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker, Gerard Davis, Nicolette Jeanblanc, Susan Brophy, Bruce Dille
-
Publication number: 20180179272Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.Type: ApplicationFiled: November 22, 2017Publication date: June 28, 2018Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
-
Patent number: 9862762Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.Type: GrantFiled: February 5, 2015Date of Patent: January 9, 2018Assignee: MEDIMMUNE, LLCInventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
-
Publication number: 20170173149Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: April 7, 2015Publication date: June 22, 2017Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Publication number: 20170114151Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.Type: ApplicationFiled: August 8, 2016Publication date: April 27, 2017Inventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
-
Patent number: 9580509Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.Type: GrantFiled: November 6, 2012Date of Patent: February 28, 2017Assignee: MedImmune, LLCInventors: Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Mladen Tomich, Reena Varkey, Partha S. Chowdhury, Ralph Minter, Sandrine Guillard, Steven Rust, Vignesh Venkatraman
-
Patent number: 9527905Abstract: Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.Type: GrantFiled: February 7, 2012Date of Patent: December 27, 2016Assignee: MedImmune, LLCInventors: Bret Sellman, Christine Tkaczyk, Lei Hua, Partha Chowdhury, Reena Varkey, Melissa Damschroder, Li Peng, Vaheh Oganesyan, Jamese Johnson Hilliard
-
Publication number: 20160311894Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.Type: ApplicationFiled: February 5, 2015Publication date: October 27, 2016Inventors: Partha Chowdhury, Reena Varkey, Meina Liang, Yen-Wah Lee, Katie Streicher, Koustubh Ranade, Ethan Grant, Lydia Greenlees, Yihong Yao, Melissa Parker
-
Publication number: 20150284450Abstract: The disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: November 6, 2013Publication date: October 8, 2015Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, Sandrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao